Processa Pharmaceuticals (PCSA) EBIT Margin (2012 - 2016)
Processa Pharmaceuticals' (PCSA) quarterly EBIT Margin came in at 1510.3% in Q1 2016, down 11109.0% YoY from N/an in Q2 2015, and down 21.72% on a QoQ basis from 1240.75% in Q4 2015.
Processa Pharmaceuticals (PCSA) EBIT Margin (2012 - 2016) Analysis & Trends
Processa Pharmaceuticals (PCSA) has 5 years of EBIT Margin data on file, last reported at 1510.3% in Q1 2016.
- Quarterly EBIT Margin fell 11109.0% year-over-year to 1510.3% in Q1 2016, while the trailing twelve-month figure through Dec 2016 was 1430.52% (up 163125.0% YoY) and the FY2016 annual result came in at 1430.52%, up 94205.0% from the prior year.
- EBIT Margin fell to 1510.3% in Q1 2016, from 1240.75% in the prior quarter.
- In the past five years, EBIT Margin ranged from a high of 417.6% in Q2 2012 to a low of 9955.25% in Q1 2014.
- A 5-year average of 2612.4% and a median of 1249.21% in 2014 frame the typical range for EBIT Margin.
- The widest YoY moves for EBIT Margin: up 855604 bps in 2015, down 847579 bps in 2015.
- Tracing PCSA's EBIT Margin over 5 years: stood at 2440.49% in 2012, then soared by 54 bps to 1130.78% in 2013, then sank by 321 bps to 4764.38% in 2014, then jumped by 74 bps to 1240.75% in 2015, then dropped by 22 bps to 1510.3% in 2016.
- The last three EBIT Margin figures came in at 1510.3% (Q1 2016), 1240.75% (Q4 2015), and 709.83% (Q3 2015), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 17.93% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -35.57% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.36% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.75% |
| 10 | Processa Pharmaceuticals | 5.69 Mn | 5.69 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2016 | -1,510.30% |
| Dec 31, 2015 | -1,240.75% |
| Sep 30, 2015 | -709.83% |
| Jun 30, 2015 | -9,434.57% |
| Mar 31, 2015 | -1,399.21% |
| Dec 31, 2014 | -4,764.38% |
| Sep 30, 2014 | -1,257.66% |
| Jun 30, 2014 | -958.78% |
| Mar 31, 2014 | -9,955.25% |
| Dec 31, 2013 | -1,130.78% |
| Sep 30, 2013 | -535.64% |
| Jun 30, 2013 | -712.59% |
| Mar 31, 2013 | -4,172.48% |
| Dec 31, 2012 | -2,440.49% |
| Sep 30, 2012 | -1,158.02% |
| Jun 30, 2012 | -417.60% |